Boothbay Fund Management, LLC Aldeyra Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$5.77 - $9.93 $17,286 - $29,750	2,996 Added 22.15%	16,521 $164,000
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $68,707 - $95,892	13,525 New	13,525 $94,000
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $6,974 - $13,919	2,870 Added 5.39%	56,082 $224,000
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $172,939 - $275,106	53,212 New	53,212 $237,000
Q1 2021 May 17, 2021	SELL	$6.53 - $14.42 $119,348 - $263,554	-18,277 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$6.31 - $8.13 $115,327 - $148,592	18,277 New	18,277 $125,000
Q3 2020 Nov 16, 2020	SELL	$4.0 - $7.53 $48,300 - $90,924	-12,075 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $1,132 - $2,903	575 Added 5.0%	12,075 $50,000
Q1 2020 May 15, 2020	BUY	$1.62 - $6.4 $18,630 - $73,600	11,500 New	11,500 $28,000
Q2 2019 Aug 14, 2019	SELL	$6.0 - $9.0 $820,800 - $1.23 Million	-136,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$7.14 - $9.85 $834,294 - $1.15 Million	116,848 Added 585.65%	136,800 $1.24 Million
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $144,851 - $265,162	19,952 New	19,952 $166,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $274M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.